Intelligent Bio Solutions (Intelligent Bio Solutions) Operating Income : $-10.11 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Operating Income?

Intelligent Bio Solutions's Operating Income for the three months ended in Mar. 2024 was $-2.95 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.11 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Intelligent Bio Solutions's Operating Income for the three months ended in Mar. 2024 was $-2.95 Mil. Intelligent Bio Solutions's Revenue for the three months ended in Mar. 2024 was $0.82 Mil. Therefore, Intelligent Bio Solutions's Operating Margin % for the quarter that ended in Mar. 2024 was -358.50%.

Intelligent Bio Solutions's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Intelligent Bio Solutions's annualized ROC % for the quarter that ended in Mar. 2024 was -128.46%. Intelligent Bio Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1,208.41%.

Intelligent Bio Solutions Operating Income Historical Data

The historical data trend for Intelligent Bio Solutions's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Operating Income Chart

Intelligent Bio Solutions Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Operating Income

Get a 7-Day Free Trial

-6.73

-2.86

-5.57

-8.34

-8.44

Intelligent Bio Solutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Income	Get a 7-Day Free Trial															-2.45	-2.64	-2.53	-1.99	-2.95

Intelligent Bio Solutions Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.11 Mil.

Intelligent Bio Solutions (NAS:INBS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Intelligent Bio Solutions's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-11.816 * ( 1 - 0% )	/	( (9.302	+	9.095)	/ 2 )
=	-11.816	/	9.1985
=	-128.46 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.827	-	1.763	-	( 1.119	-	max(0, 5.183	-	2.945	+	1.119	))
=	9.302

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17.039	-	2.129	-	( 9.398	-	max(0, 5.706	-	11.521	+	9.398	))
=	9.095

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Intelligent Bio Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.776	/	( ( (1.024 + max(-3.025, 0))	+	(0.925 + max(-3.286, 0)) )	/	2 )
=	-11.776	/	( ( 1.024	+	0.925 )	/	2 )
=	-11.776	/	0.9745
=	-1,208.41 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.263	+	0.942	+	0.332)	-	(1.763	+	2.432	+	0.367)
=	-3.025

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.432	+	0.878	+	0.481)	-	(2.129	+	2.289	+	0.659)
=	-3.286

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Intelligent Bio Solutions's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.954	/	0.824
	=	-358.50 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Intelligent Bio Solutions Operating Income Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

12Q:Germany

Address

57th Street, 142 West, 11th Floor, New York, NY, USA, 10019

Website

https://www.gbs.inc

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

Executives

Harry Simeonidis	director, officer: CEO, President	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins	director	P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg	director	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris	officer: Chief Financial Officer	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd	10 percent owner	LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers	director	1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher	director	C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017